Molecularly Imprinted Nanomedicine for Anti-angiogenic Cancer Therapy via Blocking Vascular Endothelial Growth Factor Signaling
Related Experiment Video
Updated: Jul 16, 2025
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Published on: September 27, 2013
Menghuan Zhao1, Peixin Guan1, Shuxin Xu1
1State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China.
Abstract:
The VEGF-VEGFR2 (VEGF = vascular endothelial growth factor) signaling has been a promising target in cancer therapy. However, because conventional anti-angiogenic therapeutics suffer from drawbacks, particularly severe side effects, novel anti-angiogenic strategies are much needed. Herein, we report the rational engineering of VEGF-targeted molecularly imprinted polymer nanoparticles (nanoMIP) for anti-angiogenic cancer therapy. The anti-VEGF nanomedicine was prepared via a state-of-the-art molecular imprinting approach using the N-terminal epitope of VEGF as the template. The nanoMIP could target the two major pro-angiogenic isoforms (VEGF165 and VEGF121) with high affinity and thereby effectively block the VEGF-VEGFR2 signaling, yielding a potent anti-angiogenic effect of "killing two birds with one stone". In vivo experiments demonstrated that the anti-VEGF nanoMIP effectively suppressed tumor growth via anti-angiogenesis in a xenograft model of human colon carcinoma without apparent side effects. Thus, this study not only proposes an unprecedented anti-angiogenic strategy for cancer therapy but also provides a new paradigm for the rational development of MIPs-based "drug-free" nanomedicines.
Insights
Engineered nanoparticles targeting vascular endothelial growth factor (VEGF) offer a novel cancer therapy. This drug-free approach effectively inhibits tumor growth by blocking VEGF-VEGFR2 signaling without severe side effects.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Vascular endothelial growth factor (VEGF) signaling is crucial for tumor angiogenesis and progression.
- Conventional anti-angiogenic therapies face challenges due to severe side effects.
- Novel strategies are needed to target VEGF effectively and safely in cancer treatment.
Purpose of the Study:
- To rationally engineer VEGF-targeted molecularly imprinted polymer nanoparticles (nanoMIP) for anti-angiogenic cancer therapy.
- To develop a "drug-free" nanomedicine approach for cancer treatment.
- To evaluate the efficacy and safety of nanoMIP in preclinical cancer models.
Main Methods:
- Molecular imprinting technique using the N-terminal epitope of VEGF as a template.
- Preparation and characterization of VEGF-specific nanoMIP.
- In vivo evaluation of anti-tumor efficacy and side effects in a human colon carcinoma xenograft model.
Main Results:
- The developed nanoMIP demonstrated high affinity targeting of pro-angiogenic VEGF isoforms (VEGF165 and VEGF121).
- nanoMIP effectively blocked VEGF-VEGFR2 signaling, leading to potent anti-angiogenic effects.
- In vivo studies showed significant suppression of tumor growth with no apparent side effects.
Conclusions:
- Rational engineering of nanoMIP provides a promising new strategy for anti-angiogenic cancer therapy.
- This "drug-free" nanomedicine approach offers a safe and effective alternative to conventional therapeutics.
- The study establishes a new paradigm for developing molecularly imprinted polymer-based nanomedicines.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Regulation of Angiogenesis and Blood Supply
02:38Mitogens and the Cell Cycle
01:10Mechanism of Angiogenesis